SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

AMBROSIO, Maria Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.815
AS - Asia 8.168
EU - Europa 6.302
SA - Sud America 1.429
AF - Africa 138
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 30.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.461
SG - Singapore 3.549
CN - Cina 2.350
DE - Germania 2.278
BR - Brasile 1.223
IT - Italia 935
UA - Ucraina 840
HK - Hong Kong 780
RU - Federazione Russa 527
GB - Regno Unito 476
VN - Vietnam 462
TR - Turchia 459
FI - Finlandia 395
SE - Svezia 236
PL - Polonia 207
MX - Messico 170
CA - Canada 155
ID - Indonesia 118
IN - India 105
FR - Francia 102
AR - Argentina 87
NL - Olanda 78
ZA - Sudafrica 68
JP - Giappone 65
BD - Bangladesh 62
ES - Italia 53
IQ - Iraq 42
LT - Lituania 38
AT - Austria 34
BE - Belgio 34
EC - Ecuador 28
PK - Pakistan 24
UZ - Uzbekistan 24
VE - Venezuela 23
CO - Colombia 20
MA - Marocco 19
AE - Emirati Arabi Uniti 13
PY - Paraguay 12
SA - Arabia Saudita 12
EG - Egitto 11
AL - Albania 10
IE - Irlanda 10
KE - Kenya 10
MY - Malesia 10
RO - Romania 10
AU - Australia 9
CL - Cile 9
JO - Giordania 9
UY - Uruguay 9
BO - Bolivia 8
CZ - Repubblica Ceca 8
NP - Nepal 8
PE - Perù 8
TN - Tunisia 8
CH - Svizzera 7
DZ - Algeria 7
IR - Iran 7
EU - Europa 6
IL - Israele 6
AZ - Azerbaigian 5
KR - Corea 5
LB - Libano 5
PH - Filippine 5
SY - Repubblica araba siriana 5
TH - Thailandia 5
DO - Repubblica Dominicana 4
JM - Giamaica 4
KG - Kirghizistan 4
NG - Nigeria 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
DK - Danimarca 3
GR - Grecia 3
LK - Sri Lanka 3
LV - Lettonia 3
TW - Taiwan 3
BG - Bulgaria 2
BY - Bielorussia 2
CY - Cipro 2
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
QA - Qatar 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
BW - Botswana 1
Totale 30.855
Salva come PNG Salva come JPEG
Città #
Singapore 2.089
Ashburn 1.560
Woodbridge 1.317
Fairfield 1.155
Chandler 1.111
Jacksonville 897
Santa Clara 814
Houston 803
Beijing 799
Hong Kong 777
Ann Arbor 506
Wilmington 443
Seattle 442
Cambridge 359
Munich 318
Los Angeles 299
New York 285
Izmir 280
Dallas 276
Nanjing 265
Princeton 227
Addison 216
Warsaw 201
Milan 155
San Diego 154
Shanghai 147
Ho Chi Minh City 146
Ferrara 142
São Paulo 137
Helsinki 125
Mexico City 120
Boardman 116
Hanoi 113
Turku 91
Jakarta 87
Shenyang 78
London 71
Hebei 70
Nanchang 70
Hefei 69
Washington 68
Bremen 66
Chicago 64
Tokyo 60
Brooklyn 58
Denver 58
Dearborn 56
Buffalo 55
Tianjin 55
Montreal 53
Changsha 52
Orem 52
Moscow 51
Chennai 48
Stockholm 47
Mountain View 46
Johannesburg 44
Jiaxing 43
Toronto 43
San Francisco 41
Boston 40
Rome 39
Phoenix 38
Falls Church 37
Atlanta 36
Bologna 36
Poplar 36
Redwood City 35
Brussels 34
Rio de Janeiro 34
Jinan 33
Kunming 33
Frankfurt am Main 31
Belo Horizonte 27
Guangzhou 27
San Jose 27
Ankara 26
Manchester 26
Nuremberg 26
Ningbo 24
Norwalk 23
The Dalles 23
Zhengzhou 22
Falkenstein 21
Brasília 20
Campinas 19
Des Moines 18
Haiphong 18
Ottawa 18
San Mateo 18
Tashkent 18
Curitiba 17
Modena 17
Amsterdam 16
Biên Hòa 15
Hangzhou 15
Hải Dương 15
Orange 15
Tappahannock 15
Auburn Hills 14
Totale 19.392
Salva come PNG Salva come JPEG
Nome #
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 285
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 258
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 242
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 221
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 214
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 208
Circadian profile of plasma calcitonin gene-related peptide in healthy man 202
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 201
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 200
Acute lowering of plasma GH concentrations by somatostatin is associated with activation of pituitary-adrenal-axisin healthy young and elderly subjects 195
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 193
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 193
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 191
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 189
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 187
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 185
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone (GH)- releasing hormone function 176
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 174
Efficacy and safety of the new 60 mg formulation of the long acting somatostatin analog lanreotide in the treatment of acromegaly. 174
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 174
Growth hormone excess promotes breast cancer chemoresistance 174
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 174
R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism 174
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 173
Growth hormone induces chemoresistance in breast cancer cells 171
Antiproliferative effects of somatostatin analogs in pituitary adenomas 170
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 170
Evaluation of hormonal function in a series of incidentally discovered adrenal masses 168
Therapeutic concentrations of mitotane (o,p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model 168
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 168
Diurnal rhythm of plasma catecholamines in acromegaly 167
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 166
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 165
A defective hypothalamic GHRH activity may contribute to declining GH secretion wuth age in man 163
Neck paraganglioma and follicular lymphoma: A case report 163
Effects of octreotide on gallbladder motor function in acromegaly 162
Pituitary side effects of old and new drugs. 161
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 160
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 160
A new VHL polymorphism in a big family from Ferrara 160
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 159
ADRENAL INCIDENTALOMA: CLINICAL AND METABOLIC ASPECTS DURING LONG-TERM FOLLOW-UP 157
In vitro testing of new somatostatin analogs on pituitary tumor cells 156
Atypical femoral fractures as a complication of long-term bisphosphonate therapy 155
Efficacy of tolvaptan treatment in a patient with syndrome of inappropriate antidiuresis (SIAD) after severe traumatic brain injury 155
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience 154
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 154
Growth hormone and skeletal muscle function 154
Prevalence and predictive factors of anterior hypopituitarism after ischemic stroke. 154
Cerebral aneurysm and acromegaly: a case report 153
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 153
Cardiac and metabolic effects of chronic GH and IGF1 excess in young adults with pituitary gigantism 153
A tool to predict survival in stage IV entero-pancreatic NEN 152
EFFECTS OF SOMATOSTATIN ANALOG TREATMENT ON GLUCOSE METABOLISM IN ACROMEGALY 151
GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis 151
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI) 151
Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women 150
Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study 149
RISK FACTORS FOR DEVELOPING HYPOPITUITARISM AFTER STROKE 148
Blood GH-binding protein levels in premenopausal and postmenopausal women: role of body weight and estrogen levels 147
Efficay and safety of everolimus in metastatic gastroenteropancreatic neuroendocrine tumors 146
Post-stroke inflammatory response may influence pituitary function in patients with brain ischemic and hemorrhagic injury 146
Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-κB 146
Efficacy, safety and adherence to treatment of teriparatide: an observational study 145
Endogenous estrogen status significantly influences the nutrition-related alterations in Growth Hormone-Binding protein levles in healthy women 144
Le alterazioni pressorie nell'acromegalia: fattori umorali 144
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 144
Functional hypothalamic and drug-induced amenorrhea: an overview 144
Growth Hormone enhances breast cancer chemoresistance by protecting from apoptosis 143
Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major 143
Role of Piuitary Tumour Transforming Gene 1 in medullary thyroid carcinoma 142
GH influences breast cancer chemoresistanec independently of cell cycle perturbations 142
Delta opioid receptor involvement in endocrine pathophysiology 141
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 141
Glucose metabolism alterations in acromegaly 141
Inflammatory cytokines and neurotrophic factors correlate with pituitary function after stroke 140
Everolimus reduces human ACTH-secreting pituitary adenoma in vitro cell viability 138
Cerebrovascular disease and GH-IGF-i axis function 138
Lumbar spine mineral density Z-score discrepancy by DXA and QCT in thalassaemic major patients 138
Everolimus reduces human ACTH secreting pituitary adenoma in vitro cell viability by inhibiting IGF-I down-stream signalling 137
Prevalence of hyopituitarism in post-acute and chronic phase of hemorrhagic stroke 137
ASSE GH-IGF-I NELL'INVECCHIAMENTO 136
Real-world study of everolimus in advanced progressive neuroendocrine tumors 136
Percutaneous Laser Ablation of Liver Metastases from Neuroendocrine Neoplasm. A Retrospective Study for Safety and Effectiveness 136
ASYMPTOMATIC HYPERCALCITONINEMIA IN A PANCREATIC ENDOCRINE CARCINOMA ASSOCIATED WITH A PAPILLARY THYROID CANCER 135
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 134
Dopamine receptor 2 activation reduces cells viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 134
Interrelationships between calcitonin gene-related peptide and sympathoadrenomedullary system: Effects of administration of epinephrine and norepinephrine in healthy man 133
Replacement therapy and quality of life improvement in adult GHD patients 132
Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man 131
GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells 130
Apoplessie in una casistica di adenomi ipofisari 130
Ovarian tumors secreting insulin 130
null 130
Prevalence of hypopituitarismin patients with cerebrovascular diseases 128
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 128
Bone metastases frequency, distribution, clinical and imaging characteristics in neuroendocrine tumors: our experience 127
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 126
Human galanin reduces plasma norepinephrine levels in man 123
Follow-up dei pazienti sottoposti a terapia chirurgica per adenomi ipofisari non secernenti. 123
Totale 15.917
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.701
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 11.162
Totale 160.863
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.242 0 0 0 0 0 212 64 235 66 269 288 108
2021/20221.981 58 208 114 57 89 90 96 90 79 162 187 751
2022/20232.357 234 221 90 310 328 341 127 205 282 26 119 74
2023/20241.350 108 142 73 41 102 263 48 150 45 30 31 317
2024/20255.557 157 149 427 183 640 580 206 198 906 687 782 642
2025/20268.618 1.472 611 1.302 1.891 2.491 851 0 0 0 0 0 0
Totale 31.208